News and Media
This Saturday, MMS is hosting their annual Scientific Symposium India at its Asian headquarters in Bangalore, India. RSVP now at: Asia@mmsholdings.com
MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study
Canton, Mich. (July 10, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today its integrated support for Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH). MMS supported data aspects for Gemphire in achieving its primary endpoint…
Durham, N.C. (June 13, 2018) – MMS Holdings Inc. (MMS) – a leading global clinical research organization – announced today that Lisa James has joined as Director, Business Operations and Client Relations. James brings a depth of industry and business experience, having most recently held the position as Director of Corporate Operations at Health Decisions, Inc.
Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
Canton, Mich. and Findlay, Ohio (May 1, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that they have partnered with the University of Findlay to provide online medical writing and clinical trial disclosures courses to students at the university and across the globe.
Posted April 19, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today the hiring of John Mitcheson as Senior Proposal Development Manager and Joy Willard, RN, BSN, PMP as Senior Project Manager in response to double digit company growth in North Carolina for the past three years.
Posted April 13, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This platform offers education to all MMS colleagues across North America, Europe, India, and South Africa in a variety of formats from instructor led to self-directed sessions.
MMS is proud to announce that Mary Anne Potok, Technical Manager, Regulatory Operations will be speaking at the PhUSE single day event in Boston on April 26, 2018. Hosted at Vertex Pharmaceuticals, the theme for this event is Practical…
Poster November 15, 2017
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Since its selection in June, MMS has been assisting in drafting, assembling and publishing the clinical components of the omadacycline NDAs for the U.S. Food and Drug Administration (FDA) in acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Posted November 2, 2017
MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.”